Impaired autophagy: a link between neurodegenerative diseases and progressive myoclonus epilepsies

Trends Mol Med. 2011 Jun;17(6):293-300. doi: 10.1016/j.molmed.2011.02.005. Epub 2011 Apr 7.

Abstract

In recent years, research into the molecular bases of neurodegenerative diseases has progressed, and therapies have been developed to combat the causative agents. Based on the observation that progressive myoclonus epilepsies (PMEs) and neurodegenerative diseases share common features of neurodegeneration, we propose that the two pathologies share common underlying molecular characteristics. It is well documented that autophagy is overloaded or impaired in neurodegenerative conditions, and it is also impaired in some PMEs, the clearest example being EPM2 (Lafora disease). Although more research into this connection is warranted, we propose that existing therapies for PMEs could be augmented with similar drugs as those used for neurodegenerative diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autophagy / drug effects
  • Autophagy / physiology*
  • Biomarkers
  • Carrier Proteins / genetics
  • Cystatin B / genetics
  • Humans
  • Microtubule-Associated Proteins / genetics
  • Microtubule-Associated Proteins / immunology
  • Models, Biological
  • Myoclonic Epilepsies, Progressive* / genetics
  • Myoclonic Epilepsies, Progressive* / physiopathology
  • Myoclonic Epilepsies, Progressive* / therapy
  • Neurodegenerative Diseases* / genetics
  • Neurodegenerative Diseases* / physiopathology
  • Oxidative Stress / physiology
  • Protein Tyrosine Phosphatases, Non-Receptor / genetics
  • Sirolimus / pharmacology
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • Ubiquitin-Protein Ligases

Substances

  • Biomarkers
  • CSTB protein, human
  • Carrier Proteins
  • MAP1LC3A protein, human
  • Microtubule-Associated Proteins
  • Cystatin B
  • NHLRC1 protein, human
  • Ubiquitin-Protein Ligases
  • TOR Serine-Threonine Kinases
  • Protein Tyrosine Phosphatases, Non-Receptor
  • EPM2A protein, human
  • Sirolimus